157 related articles for article (PubMed ID: 23197234)
1. Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.
Jaeger BA; Tauer JT; Ulmer A; Kuhlisch E; Roth HJ; Suttorp M
Med Sci Monit; 2012 Dec; 18(12):CR721-8. PubMed ID: 23197234
[TBL] [Abstract][Full Text] [Related]
2. Altered bone and mineral metabolism in patients receiving imatinib mesylate.
Berman E; Nicolaides M; Maki RG; Fleisher M; Chanel S; Scheu K; Wilson BA; Heller G; Sauter NP
N Engl J Med; 2006 May; 354(19):2006-13. PubMed ID: 16687713
[TBL] [Abstract][Full Text] [Related]
3. Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.
Giona F; Mariani S; Gnessi L; Moleti ML; Rea M; De Vellis A; Marzella D; Testi AM; Foà R
Haematologica; 2013 Mar; 98(3):e25-7. PubMed ID: 22983586
[No Abstract] [Full Text] [Related]
4. Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib.
Jönsson S; Standal T; Olsson B; Mellström D; Wadenvik H
Am J Hematol; 2012 May; 87(5):550-2. PubMed ID: 22407760
[TBL] [Abstract][Full Text] [Related]
5. Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate.
Yang KH; Park SY; Park SW; Lee SH; Han SB; Jung WK; Kim SJ
J Bone Miner Metab; 2010 Nov; 28(6):713-8. PubMed ID: 20607326
[TBL] [Abstract][Full Text] [Related]
6. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
7. Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.
Vandyke K; Fitter S; Drew J; Fukumoto S; Schultz CG; Sims NA; Yeung DT; Hughes TP; Zannettino AC
J Clin Endocrinol Metab; 2013 Jan; 98(1):67-76. PubMed ID: 23144472
[TBL] [Abstract][Full Text] [Related]
8. Bone metabolism during long-term treatment with imatinib.
O'Sullivan S; Horne A; Wattie D; Porteous F; Gamble G; Browett P; Grey A
Leuk Lymphoma; 2013 Aug; 54(8):1783-5. PubMed ID: 23278638
[No Abstract] [Full Text] [Related]
9. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib.
O'Sullivan S; Horne A; Wattie D; Porteous F; Callon K; Gamble G; Ebeling P; Browett P; Grey A
J Clin Endocrinol Metab; 2009 Apr; 94(4):1131-6. PubMed ID: 19174494
[TBL] [Abstract][Full Text] [Related]
10. TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model.
Ulmer A; Tabea Tauer J; Glauche I; Jung R; Suttorp M
Klin Padiatr; 2013 May; 225(3):120-6. PubMed ID: 23716272
[TBL] [Abstract][Full Text] [Related]
11. Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.
Bansal P; Ghalaut VS; Sharma TK; Ghalaut PS; Dokwal S; Ghalaut R; Kulshrestha M; Dahiya K
Clin Lab; 2014; 60(11):1845-52. PubMed ID: 25648025
[TBL] [Abstract][Full Text] [Related]
12. [Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia].
Zhong JS; Meng FY; Xu D; Zhou HS; Dai M
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):177-82. PubMed ID: 22781602
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
14. Management of the new patient with CML in chronic phase.
Marin D
Curr Hematol Malig Rep; 2013 Mar; 8(1):37-42. PubMed ID: 23381448
[TBL] [Abstract][Full Text] [Related]
15. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.
Millot F; Baruchel A; Guilhot J; Petit A; Leblanc T; Bertrand Y; Mazingue F; Lutz P; Vérité C; Berthou C; Galambrun C; Bernard F; Yacouben K; Bordigoni P; Edan C; Reguerre Y; Couillault G; Méchinaud F; Cayuela JM; Guilhot F
J Clin Oncol; 2011 Jul; 29(20):2827-32. PubMed ID: 21670449
[TBL] [Abstract][Full Text] [Related]
16. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
17. Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
Ernst T; Hoffmann J; Erben P; Hehlmann R; Hochhaus A; Müller MC
Clin Chem Lab Med; 2008; 46(3):318-22. PubMed ID: 18303987
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Cervera E; Candelaria M; López-Navarro O; Labardini J; Gonzalez-Fierro A; Taja-Chayeb L; Cortes J; Gordillo-Bastidas D; Dueñas-González A
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):207-12. PubMed ID: 22420986
[TBL] [Abstract][Full Text] [Related]
19. Endogenous erythroid colony formation in chronic myeloid leukemia: a recurrent finding associated with persistent minimal residual disease under imatinib.
Einwallner E; Jaeger E; Mitterbauer-Hohendanner G; Bilban M; Simonitsch-Klupp I; Steiner I; Pernicka E; Hoermann G; Herndlhofer S; Sillaber C; Valent P; Schwarzinger I
Stem Cells Dev; 2013 Dec; 22(23):3043-51. PubMed ID: 23883175
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
